Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFTAZIDIME vs KEFUROX
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
Cefuroxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Treatment of infections caused by susceptible Gram-negative bacteria, including lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bone and joint infections, intra-abdominal infections, central nervous system infections (meningitis), and septicemia.,Empiric therapy for febrile neutropenia.,Off-label: treatment of melioidosis (Burkholderia pseudomallei infection).
Lower respiratory tract infections (e.g., pneumonia, acute bacterial exacerbations of chronic bronchitis),Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis, tonsillitis),Skin and skin structure infections,Urinary tract infections,Gonorrhea (uncomplicated),Early Lyme disease,Septicemia,Meningitis
1-2 g IV every 8 hours
750 mg to 1.5 g intramuscularly or intravenously every 8 hours; for severe infections, 1.5 g intravenously every 6 to 8 hours.
2 hours (range 1.2-2.2 h) in normal renal function; prolonged to 10-15 h in end-stage renal disease; requires dose adjustment.
1.2-1.6 hours in adults with normal renal function (Clcr >80 m L/min); prolonged to 10-20 hours in end-stage renal disease (Clcr <10 m L/min).
Ceftazidime is not metabolized; it is excreted unchanged in the urine via glomerular filtration. Approximately 80-90% of a dose is recovered in the urine within 24 hours.
Cr Cl 31-50 m L/min: 1 g every 12 hours; Cr Cl 16-30 m L/min: 1 g every 24 hours; Cr Cl 6-15 m L/min: 500 mg every 24 hours; Cr Cl <5 m L/min: 500 mg every 48 hours
GFR 50-20 m L/min: 750 mg every 12 hours; GFR 20-10 m L/min: 750 mg every 24 hours; GFR <10 m L/min: 750 mg every 48 hours; hemodialysis: 750 mg after each dialysis session.
No FDA black box warning.
Ceftazidime is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate, well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. Based on available data, ceftazidime does not appear to be associated with major teratogenic effects when used in the first trimester. However, exposure during the second and third trimesters may be considered relatively safe, but data are limited to case reports and small studies.
No evidence of teratogenicity in animal studies. Insufficient human data; risk cannot be excluded. Use only if clearly needed during pregnancy.
Ceftazidime is a third-generation cephalosporin with potent activity against Pseudomonas aeruginosa. It is often used in combination with other agents for empiric coverage in febrile neutropenia. Note that ceftazidime has poor activity against gram-positive organisms and anaerobes; consider adding vancomycin or metronidazole if these pathogens are suspected. Dose adjustment is required in renal impairment; calculate Cr Cl before administration. Avoid in patients with cephalosporin allergy or severe penicillin hypersensitivity (risk of cross-reactivity).
KEFUROX (cefuroxime) is a second-generation cephalosporin with activity against Gram-positive cocci (except MRSA and enterococci) and some Gram-negative bacilli including Haemophilus influenzae and Neisseria gonorrhoeae. It is renally eliminated; adjust dose in Cr Cl <30 m L/min. Administer with food to reduce GI upset. For serious infections, consider IV formulation due to incomplete oral absorption. Monitor for hypersensitivity reactions, especially in penicillin-allergic patients (cross-reactivity ~10%). Use with caution in patients with history of colitis.
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
"Warfarin may increase the anticoagulant activities of Ceftazidime."
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."
No interactions on record
CEFTAZIDIME and KEFUROX are distinct pharmacological agents. CEFTAZIDIME belongs to the Cephalosporin Antibiotic class and is primarily used for Treatment of infections caused by susceptible Gram-negative bacteria, including lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bone and joint infections, intra-abdominal infections, central nervous system infections (meningitis), and septicemia.Empiric therapy for febrile neutropenia.Off-label: treatment of melioidosis (Burkholderia pseudomallei infection).. KEFUROX belongs to the Cephalosporin Antibiotic class and is primarily used for Lower respiratory tract infections (e.g., pneumonia, acute bacterial exacerbations of chronic bronchitis)Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis, tonsillitis)Skin and skin structure infectionsUrinary tract infectionsGonorrhea (uncomplicated)Early Lyme diseaseSepticemiaMeningitis. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CEFTAZIDIME carries a safety status of Category A/B, whereas KEFUROX safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Cefuroxime is not metabolized and is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal: 80-90% excreted unchanged in urine via glomerular filtration; small amount (≈1%) biliary; ≤1% fecal.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
10-17% (low binding; primarily to albumin).
50-60% (primarily to albumin).
0.13-0.22 L/kg; low Vd indicates limited tissue penetration; increased in neonates.
0.16-0.23 L/kg (low Vd, consistent with limited extravascular distribution; primarily remains in extracellular fluid).
IM: 90-100% (well absorbed); IV: 100%.
IM: 100%; Oral: Not available (parenteral administration only).
No adjustment required; see renal adjustment
No dose adjustment required for mild to moderate hepatic impairment; Child-Pugh class C: no specific data, use with caution.
≥1 month: 30-50 mg/kg IV every 8 hours; max 2 g per dose
Children 3 months to 18 years: 30-100 mg/kg/day intravenously divided every 6 to 8 hours; maximum 6 g/day. Neonates: 30-50 mg/kg/day intravenously divided every 8 to 12 hours based on gestational and postnatal age.
Base dose on renal function; see renal adjustment
Elderly patients: no specific dose adjustment, but dose selection should be cautious based on renal function; monitor renal function and adjust per renal adjustment guidelines.
No FDA black box warning.
Hypersensitivity reactions (including anaphylaxis) in patients with penicillin or other beta-lactam allergies; Clostridioides difficile-associated diarrhea; neurotoxicity (seizures, encephalopathy) especially with renal impairment; renal function monitoring; bleeding risk due to hypoprothrombinemia; superinfection; use in pregnancy and lactation.
Hypersensitivity to ceftazidime, any component of the formulation, or other cephalosporins.
No significant food interactions. However, note that alcohol may cause a disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia) due to the methylthiotetrazole side chain. Avoid alcohol during therapy and for 48 hours after completion.
Cefuroxime absorption is enhanced when taken with food. Avoid alcohol during treatment and for 48 hours after completing therapy to prevent disulfiram-like reaction (though rare with cephalosporins, caution is advised). No specific dietary restrictions; maintain adequate hydration.
Ceftazidime is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.04-0.21. Based on this, the estimated daily dose to the infant is less than 1% of the maternal therapeutic dose. It is considered compatible with breastfeeding by the American Academy of Pediatrics. However, caution is advised, especially in neonates or infants with renal impairment, due to potential for alteration of gut flora and direct effects.
Cefuroxime is excreted into human milk in small amounts. M/P ratio not established. Consider risk-benefit; may cause alteration of infant gut flora.
Pharmacokinetic changes in pregnancy include increased volume of distribution and enhanced renal clearance, potentially leading to lower plasma concentrations. However, standard dosing (e.g., 1 g every 8 hours) is generally maintained, as most pathogens remain susceptible. For severe infections, consider higher doses (2 g every 8 hours) or more frequent administration. Monitor clinical response and consider therapeutic drug monitoring if available. No formal dose adjustment guidelines exist for pregnancy.
Increased volume of distribution and renal clearance during pregnancy may require higher doses or more frequent administration to maintain therapeutic levels. Monitor clinical response.
Take ceftazidime exactly as prescribed; complete the full course even if you feel better.,If you experience severe diarrhea, especially with blood or mucus, contact your doctor immediately.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Avoid alcohol during treatment and for at least 48 hours after the last dose to prevent disulfiram-like reaction.,Notify your doctor if you have a history of penicillin allergy or kidney disease.
Take this medication exactly as prescribed; do not skip doses or stop early even if you feel better.,You may take cefuroxime with food to decrease stomach upset.,Complete the full course of therapy to prevent resistance.,Contact your healthcare provider if you experience severe diarrhea, rash, or difficulty breathing.,Inform your doctor if you have a penicillin allergy, kidney disease, or a history of colitis.,This medication may cause dizziness; avoid driving until you know how it affects you.